Repoopulation Remedy

Transplanting synthetic stool made of beneficial microbes cures deadly diarrheal infections in two patients.

Written byBeth Marie Mole
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, GRAY'S ANATOMYPhony poo containing 33 isolates of commensal microbes cured two patients suffering from recurrent intestinal infections of Clostridium difficile after doctors infused the fake fecal matter into their colons during a colonoscopy. The successful insertion of synthetic stool, published today in Microbiome, provides hope for a much-needed treatment against diarrhea-causing, often drug-resistant infections by C. difficile, for which conventional fecal transplant therapies have failed to develop.

“Fecal bacteriotherapy, or ‘stool transplant,’ . . . has shown promising results in preliminary studies, but concerns about pathogen transmission, patient acceptance, and inability to standardize the treatment regimen remain,” the authors wrote in the study. “This proof-of-principle study demonstrates that a stool substitute mixture comprising a multi-species community of bacteria is capable of curing antibiotic-resistant C. difficile colitis.”

The two patients involved in the study suffered from a hyper-virulent strain of C. difficile known as ribotype 078, which was unscathed by courses of the antibiotic metronidazole and the “last resort” antibiotic, vancomycin. But 2 to 3 days after the synthetic stool transplant, both patients rid their symptoms and remained symptom-free for at least 6 months. Moreover, DNA sequencing of the patients’ stool samples taken ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies